Legislation to significantly expand patients’ access to medical cannabis will become law later this fall following a decision today by Maine lawmakers to override the Governor’s veto.
Everyday NORML Chapters from around the country invest countless hours in advocating for meaningful marijuana law reforms on the local, state and federal level! Here’s a brief rundown of some of their most recent accomplishments. Get involved today!
A majority of Oklahomans today voted to enact State Question 788 — a statewide voter-initiated measure that permits doctors to use their discretion to recommend medical cannabis to those patients who will benefit from it. Oklahoma is now the 31st state to legalize and regulate the use of medical cannabis under state law.
Regulators at the US Food and Drug Administration today granted market approval for Epidiolex, a prescription medicine containing a standardized formulation of plant-derived cannabidiol (CBD), for the explicit treatment of two rare forms of severe epilepsy: Lennox-Gastaut syndrome and Dravet syndrome.
KY NORML is passionate about education. And with the opioid epidemic consuming our state, we feel that it is our duty to share valuable information regarding the relationship between cannabis and opioids.
In just seven days, voters in Oklahoma will have the opportunity to decide in favor of providing much-needed medical marijuana access to patients.
A forthcoming report commissioned by the Governor’s office is set to recommend that lawmakers legalize and regulate the possession and sale of marijuana by adults.
Former Missouri Supreme Court Chief Justice and former Dean of the St. Louis University Law School, Michael A. Wolff, announces support of the New Approach Missouri Medical Marijuana Initiative.
Oklahoma voters will decide on Tuesday, June 26, on State Question 788 — a statewide voter-initiated measure that permits doctors to use their discretion to recommend medical cannabis to patients. If passed, Oklahoma will become the 31st state to legalize the possession and use of cannabis by authorized patients.
More than two-thirds of chronic pain patients registered to legally access medical cannabis products substitute marijuana for prescription opioids, according to data published in The Journal of Headache and Pain Among those patients diagnosed specifically with headache/migraine, cannabis was frequently reported as a substitute for other medications – including opiates (43 percent), anti-depressants (39 percent), NSAIDS (21 percent), triptans (8 percent), and anti-convulsants (8 percent).